Authors


Will Pizii

Latest:

Neoadjuvant chemoimmunotherapy combo shows promise in UTUC

The phase 2 study explored the combination of the PD-1 inhibitor toripalimab and chemotherapy as neoadjuvant treatment for patients with upper tract urothelial carcinoma.


University Hospitals

Latest:

Register Today! UH Urology Institute’s Fall Symposiums

University Hospitals Urology Institute is excited to announce that this coming fall, the department is hosting 2 educational courses in cutting-edge urologic specialties: female sexual health and gender care.


Allina Health Cancer Institute

Latest:

Allina Health Cancer Institute 2022 Symposium reimagines cancer care

The symposium brings together clinicians devoted to solving the disease of cancer and the many challenges associated with it.


Richard G. Harris, MD, FACS

Latest:

Letter: Declassifying Gleason 6 as a cancer would do more harm than good

"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.


Jamie Cesanek

Latest:

Abiraterone-based triplet boosts survival in de novo mCSPC

Findings from the PEACE-1 trial published in the Lancet showed that adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved overall survival in patients with de novo metastatic castration-sensitive prostate cancer.


Jennifer A. Linehan, MD

Latest:

Why favor high intensity focused ultrasound for treating localized prostate cancer?

"HIFU allows us to treat where we want and not where we don’t," writes Jennifer Linehan, MD.


Michael Parisi

Latest:

Smaller medical practices increasingly targeted for cyber attacks

Patient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.


Hal H. Atkinson, MD, MS

Latest:

The aging surgeon: A geriatrician's perspective

"We all need to revisit meaningful methods for ongoing assurance of competency specific to our fields of medicine and surgery across the physician career span," writes Hal H. Atkinson, MD, MS.


Nichole Tucker

Latest:

Novel intravesical drug delivery systems explored in bladder cancer

"TAR-200 is a sort of a pretzel device. It's a novel drug delivery mechanism that's placed inside the bladder for sustained release of gemcitabine," explains Siamak Daneshmand, MD.


Joan Naidorf, DO

Latest:

Expert advice on improving interactions with difficult patients

“Patients will never change, and demanding family members will never change. The solution to the problem is to manage the way we think about them,” writes Joan Naidorf, DO.


Nancy B. Davis, MD

Latest:

BCG-unresponsive NMIBC: Current evidence and options

Multiple investigational agents have been developed and are being studied.



Austin Richards

Latest:

Malpractice Consult: What to know about direct examination of lay witnesses

"To form a connection between the witness and the jury and establish the witness’ credibility, the witness needs to be the star," writes Austin M. Richards, Esq.


Bobby Liaw, MD

Latest:

Future Directions for the Management of Advanced Prostate Cancer

Bobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.


Deborah R. Kaye, MD, MS

Latest:

Financial toxicity is a growing concern in urologic oncology

"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.


Russ Conroy

Latest:

Dr. Agarwal on genomic testing, AI, and other developments in prostate cancer

"These tests, germline and tumor somatic testing, are extremely important and can no longer be ignored in the clinic when we see these patients," says Neeraj Agarwal, MD.


UCSF Health

Latest:

UCSF trial tests precision radiation with immunotherapy as new treatment for advanced prostate cancer

In a study published in The Lancet Oncology, UC San Francisco researchers conducted a phase 1 clinical trial assessing the combination of 177Lu-PSMA-617 and pembrolizumab in patients with metastatic castration-resistant prostate cancer.


Daniel C. Parker, MD

Latest:

How to perform office-based blue light cystoscopy

BLC with hexaminolevulinate can be an easily replicable procedure in patients with non–muscle-invasive bladder cancer.


Jim Tudor, PCA, CPC

Latest:

Trends in coding audits and what physicians can expect

Recent trends in medical audits and what physicians can expect with the CMS changes in 2021 to the documentation of E/M codes.


Daniel D. Joyce, MD

Latest:

Transurethral resection of the bladder tumor: Standard technique and new advancements

Improvement in imaging modalities may help in performance of transurethral resection of the bladder tumor.


Lee Barrett

Latest:

Smaller medical practices increasingly targeted for cyber attacks

Patient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.


Shawn Dickerson

Latest:

Expert shares key cybersecurity fundamentals and best practices

Cybersecurity training is vital because it is mandated by HIPAA.


Vivek K. Narayan, MD, MS

Latest:

Future Directions for the Management of Advanced Prostate Cancer

Bobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.


Benjamin H. Lowentritt, MD, FACS

Latest:

Prostate Cancer Treatment: Incorporating Micronized Abiraterone into Clinical Practice

In the second article of this series, Benjamin H. Lowentritt, MD, FACS, provides clinical insights on micronized abiraterone as a treatment for patients with prostate cancer.


Vanderbilt University Medical Center

Latest:

Kidney cancer expert Dr. W. Kimryn Rathmell to be appointed director of the NCI

W. Kimryn Rathmell, MD, PhD, an internationally recognized expert in kidney cancer, is Chair of the Department of Medicine and Physician-in-Chief at Vanderbilt University Medical Center.


Gordon A. Brown, DO

Latest:

Unmet Needs and Future Directions for Patients with Metastatic CSPC

Dr Gordon Brown closes his discussion on mCSPC by highlighting unmet needs in the field and ongoing initiatives that may address these needs.


Jonathan Stein, PhD

Latest:

Expert urges widespread adoption of next-generation sequencing among physicians

NGS empowers clinicians to take proactive measures to prevent disease, enables more precise diagnosis, and provides better insight on the best treatment option.


David Robinson, CFP

Latest:

UT Money Matters: Roth IRA conversions

Expert insight on pros, cons and optimal strategies when considering converting a traditional IRA to a Roth IRA.


Sanjay Patel, MD

Latest:

How to implement an ERAS pathway in your urology practice

Program encompasses patient counseling, anesthetic planning, and early mobilization.


Miguel Gonzalez-Velez, MD

Latest:

How to approach immune checkpoint inhibitor therapy in prostate cancer

Next-generation sequencing identifies subtypes that may benefit from immune checkpoint inhibitors.

© 2023 MJH Life Sciences

All rights reserved.